F
Fabrice Barlesi
Researcher at Aix-Marseille University
Publications - 666
Citations - 36214
Fabrice Barlesi is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 64, co-authored 582 publications receiving 25403 citations. Previous affiliations of Fabrice Barlesi include Institut Gustave Roussy & Nord University.
Papers
More filters
Journal ArticleDOI
Abstract CT559: Capmatinib plus osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification
Yi-Long Wu,Ji-Youn Han,Terufumi Kato,Fabrice Barlesi,Edward B. Garon,Federico Cappuzzo,Yuji Shibata,Nathalie D. Smith,Sadhvi Khanna,Riccardo Belli,A. Yovine,Daniel Sw Tan +11 more
TL;DR: The primary endpoint is the incidence of dose limiting toxicities during the first 21 days of treatment, and investigator-assessed overall response rate (ORR), duration of response (DOR), time to response (TTR), disease control rate (DCR) and progression-free survival (PFS) per the Response Evaluation Criteria in Solid Tumors version 1.1.
Journal ArticleDOI
Prédiction de la réponse aux inhibiteurs de l’EGFR dans les cancers bronchiques non à petites cellules : l’immunohistochimie disqualifiée !
Journal ArticleDOI
Devant un mésothéliome potentiellement résécable, faut-il préalablement faire une médiastinoscopie ?
Journal ArticleDOI
Chez l’animal, les anti-inflammatoires non stéroïdiens en post-opératoire nuisent à la qualité des pleurodèses par abrasion mécanique
Journal ArticleDOI
145P Everolimus for the treatment of thymic epithelial tumors (TETs): A real-world experience
J.D. Florez Arango,J.C. Benitez Montanez,Angela Botticella,Mihaela Aldea,C. Le Pechoux,Alina-Miruna Grecea,Anna Levy,C. Roux,Maxime Frelaut,Sacha Mussot,Ornella Mercier,Entesar J. Fadel,Jean-Yves Scoazec,David Planchard,Fabrice Barlesi,Benjamin Besse +15 more
TL;DR: Le Pechoux et al. as mentioned in this paper presented a phase II trial of everolimus (EVE) 10mg (DCR of 88%), which has immune modulatory activity, of interest for patients with auto-immune disorders (AIDs), detected in up to 30% of pts.